Wandercraft has secured $75 million equity and debt as part of its Series D round, funding it said will help bring Eve, the world’s first self-balancing personal exoskeleton, to market as early as 2026.
The money should also help with expanding clinical adoption of its flagship rehabilitation system, Atalante X; and developing and deploying Calvin-40, its humanoid robot.
"The momentum we’ve achieved over the past few years is extraordinary,” said CEO Matthieu Masselin. “We’ve expanded globally, launched pivotal clinical trials, readied the commercialization of Eve, our personal exoskeleton, and entered a landmark partnership with Renault Group. This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
The news comes off the back of Wandercraft’s announcement with Renault Group, whereby the car manufacturer now has a minority stake ownership and a strategic partnership with Wandercraft. The partnership brings Renault Group’s industrial expertise to scale up production of Wandercraft’s exoskeletons and industrial robots, laying the groundwork for scaling of Eve and the broader Calvin humanoid family. Renault Group is also Wandercraft’s first commercial partner and customer of Calvin-40, named for its development time of just 40 days.
Calvin-40 is an industrial-grade robot intended for physically demanding tasks and the first humanoid robot developed by a European company. Calvin-40's rapid development was made possible by using Wandercraft’s rapid development process and existing leading-edge robotics platform integrated with NVIDIA Isaac technologies, including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson edge AI platform.
